Clinicians Split On Warfarin Gene Testing As A New Standard Of Care
This article was originally published in The Gray Sheet
Executive Summary
FDA's drug and device centers are increasingly putting their weight behind the use of genetic tests to determine proper dosing of the anti-clotting drug warfarin, but convincing doctors is proving a bigger challenge